π‘ Pearl: UNa <20 with volume depletion = kidneys appropriately conserving sodium (GI/skin loss). UNa >20 with volume depletion = kidneys inappropriately wasting sodium (renal loss or mineralocorticoid deficiency).
Treatment Direction: Normal saline corrects BOTH volume AND sodium. As volume is restored, ADH appropriately turns off.
π’ EUVOLEMIC (Normal Volume) - ADH Inappropriately ON
Volume Assessment for Euvolemia
No edema (peripheral, pulmonary, or sacral)
Normal JVP (5-8 cm HβO)
No orthostatic hypotension
Normal skin turgor
Moist mucous membranes
Primary Diagnosis: SIADH (Syndrome of Inappropriate Antidiuretic Hormone)
SIADH Diagnostic Criteria (Must Meet All)
True hyponatremia (<135 mEq/L)
Decreased serum osmolality (<275 mOsm/kg)
Inappropriately concentrated urine (UOsm >100, usually >300)
Elevated urine sodium (>20-30 mEq/L on normal diet)
Clinical euvolemia
Normal thyroid function (TSH normal)
Normal adrenal function (cortisol >18-20 ΞΌg/dL)
Normal renal function (or corrected for GFR)
π SIADH Etiologies by Category
π« PULMONARY CAUSES (20-30% of SIADH)βΌ
Malignancy
Small cell lung cancer (most classic, 10-15% of SCLC patients develop SIADH)
Small cell lung cancer (most classic - 10-15% of SCLC patients)
Head and neck cancers
Pancreatic cancer
Lymphoma (Hodgkin's and non-Hodgkin's)
Thymoma
Sarcomas
GI cancers (stomach, duodenum, colon)
βοΈ POST-OPERATIVE STATE & OTHER CAUSES (5-15%)βΌ
Post-Operative
Most common in first 48-72 hours post-op
Risk factors: Major surgery, pain, nausea, opioids, stress
Combination of ADH release + hypotonic fluid administration
Other Causes
Nausea/pain/stress: Direct ADH stimulation
HIV/AIDS: Direct CNS effects or medications
Porphyria: Acute intermittent porphyria
Hereditary: Rare familial forms
Idiopathic: 10-15% (diagnosis of exclusion after full workup)
Other Euvolemic Causes (Non-SIADH)
Hypothyroidism (SEVERE Only)
TSH typically >50-100 mIU/L (not just "elevated")
Free T4 significantly low
Cortisol often also low (check!)
Mechanism: Reduced cardiac output + GFR β ADH activation
Adrenal Insufficiency
AM cortisol <3 ΞΌg/dL
ACTH stimulation test abnormal
Mechanism: Cortisol inhibits ADH; without cortisol β ADH elevated
Often with hyperkalemia, hypoglycemia
π‘ Pearl: SIADH is diagnosis of EXCLUSION. Must rule out volume depletion, hypothyroidism, and adrenal insufficiency first. Always check TSH and AM cortisol in euvolemic hyponatremia.
π‘ HYPERVOLEMIC (Volume Overload) - ADH Inappropriately ON Despite Excess Total Body Water
β οΈ Critical Prognostic Information
Hyponatremia in heart failure and cirrhosis with ascites is a VERY POOR PROGNOSTIC INDICATOR
Heart Failure Data (2024 Evidence):
Mortality Rates: Hyponatremic patients 15-31% vs normal sodium 5-16%
Hazard Ratio: On-admission hyponatremia HR 1.43-1.50 for all-cause mortality
Na <135 mEq/L: 2Γ increased mortality vs Na >135 mEq/L
Na <130 mEq/L: 3-4Γ increased mortality, very poor prognosis
Disease Severity Marker: Reflects neurohumoral activation, not just sodium problem
CRITICAL: Sodium correction does NOT improve mortality - marker, not treatment target
Cirrhosis with Ascites Data (2024 Evidence):
Na <135 mEq/L: Strong predictor of mortality and transplant-free survival
Na <130 mEq/L: Very high mortality rate (varies by Child-Pugh and MELD score)
Complications: Increased risk of hepatorenal syndrome, infections, hepatic encephalopathy
Wald 2010 hospitalized cohort (n=53,236, PMID 20142578): Community-acquired hyponatremia adjusted OR 1.52 (95% CI 1.36-1.69) for in-hospital mortality; hospital-acquired hyponatremia OR 1.66; severity gradient observed across multiple disease states [Corrected 2026-05-03 β prior version cited a non-locatable "Meta-Analysis (850,222 patients)"; replaced with the Wald cohort which is the canonical verifiable large-cohort source for the hyponatremia-mortality association]
CRITICAL: Correction rate confounded by illness severity - sicker patients get more aggressive correction
π₯ Clinical Implications:
Goals of Care Discussion: Hyponatremia signals advanced disease - time to reassess goals
Hospice Consideration: May be appropriate if refractory symptoms, NYHA Class IV, Child-Pugh C
Treatment Futility: Correcting sodium doesn't change mortality in end-stage disease
Focus on Comfort: Symptom management may take priority over sodium correction
Research Insight (2024): Recent large studies suggest relationship between correction rate and mortality may be confounded by illness severity - sicker patients receive more aggressive treatment, leading to apparent association
When encountering hypervolemic hyponatremia, ALWAYS assess:
β Prognosis and expected trajectory
β Patient/family understanding of disease severity
β Goals of care alignment with treatment intensity
β Appropriateness of palliative care consultation
Volume Assessment for Hypervolemia
Peripheral edema (2+ pitting or more)
Elevated JVP (>8 cm HβO)
Ascites (shifting dullness, fluid wave)
Pulmonary crackles (basilar or diffuse)
Weight gain (>5 lbs in week)
S3 gallop (heart failure)
"Effective Arterial Underfilling" Paradox
Despite total body volume excess:
Total body sodium: βββ (edema, ascites present)
Total body water: ββββ (water excess > sodium excess)
Effective circulating volume: β (sensed by baroreceptors)
Albumin: Severe hypoalbuminemia (<2.5 g/dL, often <2.0)
Lipids: Hyperlipidemia, lipiduria
Urine: Frothy appearance, fatty casts
Advanced CKD (Stage 4-5)
GFR: <30 mL/min (Stage 4) or <15 mL/min (Stage 5)
Mechanism: Reduced free water clearance capacity + impaired diluting ability
Often combined with: CHF, diabetes, hypertension
Volume management: Difficult - often requires dialysis
Laboratory Findings in Hypervolemic Hyponatremia
Urine Sodium
Variable depending on cause and diuretic use:
<20 mEq/L: Severe CHF, advanced cirrhosis (no diuretics) - kidneys maximally retaining sodium
>20 mEq/L: On diuretics OR nephrotic syndrome
Other Labs
UOsm: Usually >300-400 (concentrated)
BNP/NT-proBNP: Elevated in CHF
Albumin: Low in cirrhosis, nephrotic
INR: Elevated in cirrhosis
Protein/Cr ratio: >3.5 in nephrotic
π‘ Pearl: Treatment challenge in hypervolemic hyponatremia - need to remove FREE WATER preferentially (harder than it sounds). Water restriction + loop diuretics often insufficient. May need combination of salt tabs, V2 antagonists (tolvaptan), or SGLT2 inhibitors. However, always consider if aggressive correction serves patient's goals of care.
π ADH OFF Pathway: Dilute Urine (UOsm <100 mOsm/kg)
π΄ Dilute Urine Causes - ADH Appropriately OFF
Primary (Psychogenic) Polydipsia
Water intake: >15-20 L/day (exceeds kidney excretion capacity)
UOsm: Typically <50-100 mOsm/kg (maximally dilute)
Treatment: Nutritional repletion with CAREFUL monitoring
Reset Osmostat
Definition: ADH threshold shifted to lower set point
Chronic settings: Pregnancy (Na 130-135 "normal"), chronic illness, malnutrition
Function: Responds appropriately to water load/restriction around NEW set point
Serum Na: Stable at lower level (e.g., always 130-132)
Symptoms: Usually asymptomatic
Treatment: NONE needed - appropriate homeostasis at new baseline
π‘ Pearl: ADH OFF causes are RARE compared to ADH ON. Most hyponatremia has UOsm >300 (ADH contributing). If you find UOsm <100, think primary polydipsia first, then consider low solute states (beer potomania, tea & toast).
π¬ Special Situations
Pseudohyponatremia
Definition: Factitious low sodium due to lab artifact
KEY FINDING: Serum Osmolality NORMAL (280-295 mOsm/kg)
Mechanism: Lipids/proteins displace plasma volume, reducing aqueous phase where sodium is measured (indirect ISE method)
Diagnosis:
Measure serum osmolality (will be normal)
Direct ISE method gives true sodium (if available)
Treatment: NONE needed - not true hyponatremia
π‘ Pearl: Modern labs using direct ISE rarely see pseudohyponatremia. Always measure serum osmolality to confirm TRUE hyponatremia.
Hypertonic (Translocational) Hyponatremia
Definition: Osmotically active solute draws water from cells β dilutes sodium
KEY FINDING: Serum Osmolality HIGH (>295 mOsm/kg)
Most Common Cause: HYPERGLYCEMIA
Hillier 1999 (PMID 10225241): Na drops 1.6 mEq/L per 100 mg/dL when glucose β€400; 4.0 mEq/L per 100 mg/dL when glucose >400 (overall average 2.4) [Corrected 2026-05-03 β formula is piecewise per the Hillier experimental study; the older single-factor 1.6 was the 1973 Katz convention and under-corrects in DKA]
Severe DKA: Glucose 800-1000 β measured Na may appear 120-125 β apply the 4.0 factor in this range, not 1.6
TRUE sodium may be normal or HIGH!
Corrected Sodium Calculator
Corrected Na = 130 mEq/L
Formula (Hillier 1999, PMID 10225241): Corrected Na = Measured Na + factor Γ (Glucose - 100), where factor = 0.016 if Glucose β€ 400 mg/dL, 0.040 if Glucose > 400 mg/dL. The older single-factor 0.016 (Katz 1973) under-corrects in DKA.
Other Causes:
Mannitol administration
IV contrast (hyperosmolar)
Glycerol/sorbitol (rare)
Treatment: Treat hyperglycemia; sodium will auto-correct
β οΈ DANGER: Don't give hypotonic fluids thinking patient is hyponatremic! Calculate corrected sodium first. TRUE sodium is often normal or high.
π Cerebral Salt Wasting vs SIADH: The Classic Diagnostic Dilemma
The Problem: Both present identically in many ways:
Revolutionary Approach for Severe Symptomatic Hyponatremia:
β’ Protocol: 100-150 mL of 3% saline over 10-20 minutes
β’ Assessment: Check response after each bolus
β’ Repeat: Up to 3 times based on clinical improvement
β’ Target: Symptom resolution OR 4-6 mEq/L increase
β’ Evidence: SALSA trial showed superior outcomes vs continuous infusion
Serum Labs
Hyponatremia Na+ < 135
β
Serum Osm > 280
β
Pseudohyponatremia
Urine Labs
Check Urine Osm
β
Urine Osm > Serum Osm?
ADH
YES
β
ADH is ON
Contributing to hyponatremia
NO
β
β
ADH is OFF Not contributing
β
ADH shut off Na+ rising too quickly
Treatment
Use IVF with Na+ > Urine Osm
> 120: 6-8 mEq/L/day
< 115: 3% saline
β
D5W to slow correction
ADH System: Water Controller
Primary Function: Water balance regulation
Stimulus: Osmolality changes (>280-290 mOsm/kg)
Mechanism: Aquaporin-2 water channels
Assessment: Urine osmolality (master parameter)
No ADH: Urine 50-100 mOsm/kg
Max ADH: Urine 1000-1200 mOsm/kg
Aldosterone System: Sodium Controller
Primary Function: Sodium/volume balance
Stimulus: Effective blood volume changes
Mechanism: RAAS activation cascade
Assessment: Volume status, urine sodium
Volume depletion: UNa <20 mEq/L
Volume normal/excess: UNa >20 mEq/L
2024 Key Evidence Updates
SALSA Trial: RIB superior to continuous infusion
EMPAHYPO Study: SGLT2i effective for chronic SIADH
[Corrected 2026-05-03 β prior version of this table cited author/year/N/HR combinations (Woodward 2020, Chen 2022, Kang 2021 n=3,689, Tzoulis 2023 prospective HR 1.93, George 2020 ODS registry) where 5 of 6 entries could not be verified against PubMed (Tzoulis 2023 PMID 37214762 is a tolvaptan review, not a prospective HR cohort; the others returned zero PubMed matches). The qualitative framework β that overly rapid correction raises osmotic demyelination risk β is well-established, but the specific mortality HRs were unsourced. Table rebuilt below using only verifiable sources.]
Correction Speed (mEq/L/24h)
ODS Risk (qualitative)
Clinical Context
Anchor Source
<4
Very low
May be insufficient for symptomatic patients with severe hyponatremia; for chronic asymptomatic disease, slower correction is preferred
Spasovski 2014 ESH/ESE/ERA-EDTA guideline (PMID 24569496): target rise of approximately 5 mmol/L in first hour for severe symptoms; otherwise 8 mmol/L per 24h max in most patients
4-8
Low
Recommended range. High-risk patients (Na <105, hypokalemia, malnutrition, alcohol use, advanced liver disease) should target the lower end (4-6).
Spasovski 2014 (PMID 24569496); Sterns et al. (UpToDate, multiple iterations)
8-10
Moderate
Upper acceptable limit per most guidelines; SALSA trial used 12 mEq/L/24h overcorrection threshold for primary outcome
Overcorrection threshold per SALSA primary endpoint. SALSA found 17.2% (RIB) vs 24.2% (SCI) overcorrection at 24/48h, NOT significantly different (p=0.26); RIB favored on secondary endpoint (relowering treatment 41.4% vs 57.1%, p=0.04)
SALSA Baek 2021 (PMID 33104189)
>12-18
High
Risk of osmotic demyelination, especially in chronic hyponatremia and high-risk patients. Consider relowering treatment with hypotonic fluids Β± dDAVP per Sterns/Hoorn dDAVP-clamp protocol
Spasovski 2014 (PMID 24569496); ODS risk discussed without specific HRs in primary literature given confounding by illness severity
Note on mortality data: large cohort studies have associated overly-rapid correction with increased mortality, but the relationship is confounded by illness severity (sicker patients receive more aggressive correction). The 2024-era research insight in the Goals-of-Care section above flags this confounding explicitly. Specific hazard ratios should not be quoted without anchoring to a verifiable primary source.
π’ Standard Risk Patients
Target: 6-8 mEq/L per 24 hours
No major comorbidities
Sodium >115 mEq/L
No alcohol use disorder
Normal potassium
No liver disease
π‘ High-Risk Patients
Target: 4-6 mEq/L per 24 hours
Chronic severe hyponatremia (<115)
Alcoholism or malnutrition
Hypokalemia present
Liver disease
Multiple risk factors
π΄ Emergency Situations
Initial: Symptom control, then 4-6 mEq/L
Seizures or coma
Severe neurological symptoms
Respiratory arrest risk
Cerebral edema signs
Life-threatening presentation
π Understanding the Dual Hormonal Control System
Key Concept: Two Separate Systems Control Fluid Balance
ADH (Water Balance) β Aldosterone (Sodium Balance)
Clinical Relevance: Guides volume status assessment
Clinical Application of Dual System
Separate Assessment: Volume status β ADH activity
Urine Osm: Reflects ADH effect, not volume
Urine Na: Reflects aldosterone, not ADH
Mixed Disorders: Can have both systems activated
Diagnostic Key: Prevents misinterpretation
Diagnostic Integration
Step 1: Assess symptoms and chronicity
Step 2: Check serum osmolality
Step 3: Measure urine osmolality (ADH)
Step 4: Assess volume status (aldosterone)
Step 5: Integrate findings for diagnosis
Common Misunderstandings
Myth: High urine Na = volume overload
Reality: High urine Na in SIADH with euvolemia
Myth: Concentrated urine = dehydration
Reality: Concentrated urine can occur in SIADH
Key: Separate assessment prevents errors
π Emerging Therapies and Novel Approaches
SGLT2 Inhibitors for Hyponatremia
Refardt 2020 RCT (PMID 32019783): Empagliflozin 25 mg/day for 4 days, n=88 SIAD patients on background fluid restriction. Median plasma sodium increase 10 vs 7 mmol/L vs placebo (p=0.04). Greater response when baseline Na <125 mmol/L. [Corrected 2026-05-03 β prior version cited a non-existent "EMPAHYPO" trial with empagliflozin 10 mg; the only RCT used 25 mg]
Mechanism: Osmotic diuresis (urinary glucose excretion) β free water loss
Heart Failure Patients: Potential dual benefit (CV outcomes per DAPA-HF / EMPEROR-Reduced + Na correction) β note: SGLT2i for hyponatremia in HF is off-label; use established HF indications
Diabetes Patients: Possible triple benefit (glucose, Na+, CV) β same off-label caveat
Safety: Monitor for DKA (especially type 1 DM, low-carb states), genital mycotic infection, volume depletion
Protein-Urea Conversion Therapy
Conversion Ratio: 0.35g urea per 1g protein
Therapeutic Equivalent: 43g protein = 15g urea
CorePower 42 gram supplement:Available in 3 flavors, about $3.50 per bottle, can be frozen for shake-like consistency - Optimal protein source